Literature DB >> 2841332

The use of sequence-specific antibodies to identify a secondary binding site in thrombin.

G Noé1, J Hofsteenge, G Rovelli, S R Stone.   

Abstract

The peptide comprising residues 62-73 of the B-chain of human alpha-thrombin was synthesized and polyclonal antibodies raised against it. These antibodies were found to bind to the synthetic peptide, a CNBr fragment, and a proteolytic subfragment containing this sequence, as well as the entire thrombin molecule. The purified antibodies had no effect on the hydrolysis by thrombin of D-Phe-pipecolyl-Arg-p-nitroanilide and caused only a minimal decrease (20%) in the second-order rate constant for inactivation by antithrombin III. On the other hand, the antibodies competitively inhibited the binding of hirudin over the concentration range tested (0-43 nM), and a dissociation constant of 3.4 +/- 0.5 nM was found for the antibodies. The release of fibrinopeptide A from the A alpha-chain of fibrinogen by thrombin was competitively inhibited with an inhibition constant of 11.7 +/- 0.4 nM. The activation of protein C by thrombin in the presence of thrombomodulin was also inhibited by the antibodies, and an apparent inhibition constant of 10.7 +/- 1.5 nM was found. In contrast, the antibodies had no effect on the activation of protein C in the absence of thrombomodulin. These results are discussed in relation to data obtained recently on the interaction of well defined proteolytic derivatives of human alpha-thrombin with the ligands described above.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841332

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

2.  Evidence for common structural changes in thrombin induced by active-site or exosite binding.

Authors:  M A Parry; S R Stone; J Hofsteenge; M P Jackman
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

3.  Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms.

Authors:  J P Priestle; J Rahuel; H Rink; M Tones; M G Grütter
Journal:  Protein Sci       Date:  1993-10       Impact factor: 6.725

4.  Partial characterization of vertebrate prothrombin cDNAs: amplification and sequence analysis of the B chain of thrombin from nine different species.

Authors:  D K Banfield; R T MacGillivray
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme.

Authors:  P Sié; A Bezeaud; D Dupouy; G Archipoff; J M Freyssinet; J M Dugoujon; G Serre; M C Guillin; B Boneu
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin.

Authors:  H S Suidan; K J Clemetson; M Brown-Luedi; S P Niclou; J M Clemetson; J Tschopp; D Monard
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

7.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

8.  The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.

Authors:  W Bode; I Mayr; U Baumann; R Huber; S R Stone; J Hofsteenge
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

9.  Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition.

Authors:  M G Grütter; J P Priestle; J Rahuel; H Grossenbacher; W Bode; J Hofsteenge; S R Stone
Journal:  EMBO J       Date:  1990-08       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.